Answers are grounded in this paper and cite their sources.
Adoptive T cell therapies can produce objective clinical responses in patients with hematologic and solid malignancies. Genetic manipulation of T lymphocytes has been proposed as a means of increasing the potency and range of this anti-tumor activity. We now review how coupling expression of transgenic receptors with countermeasures against potent tumor immune evasion strategies is proving highly effective in pre-clinical models and describe how these approaches are being evaluated in human subjects.
No takes yet. Share an insight, caveat, or question.
Vera et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: